3 completed, 2 no longer available, 2 recruiting, 1 active not recruiting. 6 Phase 2, 3 Phase 1, 2 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Recruiting 2, Terminated 1, Unknown 1 |
| Phase 1 | 3 | Recruiting 2, Completed 1 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
| Phase 4 | 1 | Active not recruiting 1 |
Follow Granuloma, Plasma Cell: new trials by email Literature Review of Granuloma, Plasma Cell trials Research Report on Granuloma, Plasma Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors Brigatinib - Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor | Phase 1 / Phase 2 | Recruiting | Princess Maxima Center for Pediatric Oncology | 65 | 2022-08-18 | 2025-12-05 |
| Crizotinib Continuation Clinical Study crizotinib - NSCLC, ALCL | Phase 4 | Active not recruiting | Pfizer | 27 | 2021-12-27 | 2026-03-30 |
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations Oral repotrectinib (TPX-0005) - Locally Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Turning Point Therapeutics, Inc. | 75 | 2020-03-12 | 2026-09-25 |
| Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors Crizotinib - Inflammatory Myofibroblastic Tumor | Phase 2 / Phase 3 | Unknown | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 25 | 2019-02-01 | 2019-03-14 |
| Ceritinib Rare Indications Study in ALK+ Tumors Ceritinib (LDK378) - Tumors With Aberrations in ALK, Anaplastic Large Cell Lymphoma | Phase 2 | Terminated | Novartis Pharmaceuticals | 22 | 2016-05-06 | 2019-12-27 |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide - Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 140 | 2014-08-12 | 2026-06-17 |
| Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) Ceritinib - ALK-activated Tumors | Phase 1 | Completed | Novartis Pharmaceuticals | 83 | 2013-08-28 | 2020-06-09 |
| CREATE: Cross-tumoral Phase 2 With Crizotinib Crizotinib (PF-02341066) - Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor | Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 582 | 2012-09-01 | 2023-12-11 |
| Treatment With Crizotinib Single Patient Expanded Access IND 134375 Crizotinib - Inflammatory Myofibroblastic Tumour | No longer available | Jean M. Tersak, M.D. | 2017-08-29 | |||
| Managed Access Programs for LDK378, Ceritinib ceritinib - Anaplastic Lymphoma Kinase (ALK)- Positive Tumors, Non-small Cell Lung Cancer (NSCLC) | No longer available | Novartis Pharmaceuticals | 2026-04-01 |
Lymphoma, Large-Cell, Anaplastic (7) · Carcinoma, Non-Small-Cell Lung (2) · Glioblastoma (2) · Sarcoma (2) · Sarcoma, Alveolar Soft Part (2) · Sarcoma, Clear Cell (2) · Chondrosarcoma, Extraskeletal Myxoid (1) · Chondrosarcoma, Mesenchymal (1) · Dermatofibrosarcoma (1) · Fibrosarcoma (1) · Glioma (1) · Hematologic Neoplasms (1) · Histiocytoma, Angiomatoid Fibrous (1) · Histiocytoma, Malignant Fibrous (1)
Granuloma (10) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Neoplasms by Histologic Type (8) · Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphatic Diseases (7) · Lymphoma, Non-Hodgkin (7) · Lymphoma, T-Cell (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Lymphoma (6) · Neoplasms, Connective and Soft Tissue (4) · Neoplasms, Nerve Tissue (4)
Crizotinib (4) · ceritinib (3) · Capsules (1) · Doxorubicin (1) · Ifosfamide (1) · Radiation (1) · Radiotherapy (1) · Suspensions (1) · brigatinib (1) · pazopanib (1) · repotrectinib (1)
Novartis Pharmaceuticals (3) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · Jean M. Tersak, M.D. (1) · National Cancer Institute (NCI) (1) · Pfizer (1) · Princess Maxima Center for Pediatric Oncology (1) · Turning Point Therapeutics, Inc. (1)
France (5) · Italy (5) · Canada (3) · Netherlands (3) · South Korea (3) · Spain (3) · United Kingdom (3) · United States (3) · Australia (2) · Denmark (2) · Germany (2) · Russia (2) · Taiwan (2) · Belgium (1) · China (1)
Aaron R Weiss (1) · Michel Zwaan, Prof (1)
PMID 28950372, PMID 29216400, PMID 29567632, PMID 29669701, PMID 30697903, PMID 32702309, PMID 32827353, PMID 34392187, PMID 34515544, PMID 34780709, PMID 34814185, PMID 37523624
2023 (1), U10CA098543 (1), U10CA180830 (1), U10CA180886 (1)